Navigation Links
Keryx Biopharmaceuticals Announces Upcoming Poster Presentation of Zerenex™ (ferric citrate) at the 49th ERA-EDTA Congress
Date:5/21/2012

e treatment of renal disease. Keryx is developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to a Special Protocol Assessment (SPA) agreement with the FDA. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release, particularly those anticipating future clinical trials and business prospects for Zerenex (ferric citrate) may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability, and our Japanese partner's ability, to successfully and cost-effectively complete clinical trials for Zerenex (ferric citrate); the risk that the data (both safety and efficacy) from the ongoing Phase 3 trials for Zerenex (ferric citrate) will not coincide with the data analyses from previous clinical trials reported by us and our Japanese partner; our ability to meet anticipated development timelines for Zerenex due to clinical trial results, manufacturing capabilities or other factors; our ability to replicate in our ongoing long-term Phase 3 clinical study the effects on iron storage parameters, intravenous (IV) iron and erythropoiesis-stimulating agent (ESA) use observed in previous clinical trials; the ability for Zerenex to generate cost savings for dialysis centers and payers; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this pres
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
9. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
10. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2014)... , Nov. 23, 2014 Anthera Pharmaceuticals, ... Paul F. Truex , President and Chief Executive ... Annual Piper Jaffray Healthcare Conference. Anthera ... at the Palace Hotel in New York ... Anthera Pharmaceuticals is a biopharmaceutical company focused ...
(Date:11/22/2014)... -- Sprout Pharmaceuticals today announced positive preliminary results from a Phase ... up to 200 mg at bedtime had no next-day impairment ... th Annual Fall Scientific Meeting of the Sexual Medicine ... Miami . The Phase 1 driving ... and the Formal Dispute Resolution that was filed in December ...
(Date:11/22/2014)... Nov. 21, 2014  CytoSorbents Corporation (OTCQB: CTSO), ... Union approved CytoSorb® cytokine adsorber to treat critically-ill ... Beacon of Light Award at last night,s New ... Dr. Phillip Chan , Chief Executive ... to be recognized by the New Jersey Tech ...
Breaking Medicine Technology:Anthera Pharmaceuticals to Present at Annual Piper Jaffray Healthcare Conference 2Sprout Pharmaceuticals Presents Phase 1 Clinical Trial Data Showing Treatment With Flibanserin Results In No Next-Day Driving Impairment 2Sprout Pharmaceuticals Presents Phase 1 Clinical Trial Data Showing Treatment With Flibanserin Results In No Next-Day Driving Impairment 3CytoSorbents Wins Beacon of Light Award 2CytoSorbents Wins Beacon of Light Award 3CytoSorbents Wins Beacon of Light Award 4
... 29, 2011 Breast cancer patients and their families ... (FDA) decision to remove the anti-cancer drug Avastin from ... breast cancer. Terry Kalley, founder of the ... the decision, saying, "While this vote is disappointing, it ...
... Mass., June 29, 2011 NxStage® Medical, Inc. (Nasdaq: ... dialysis products, announced that it has entered into a ... move its corporate headquarters to the revitalized historic mill ... Street, Lawrence, MA.  The move, which is expected to ...
Cached Medicine Technology:Breast Cancer Patients and Families Decry FDA Panel Vote to Remove Life Saving Drug From Approved List 2NxStage® Enters Into New Lease for Corporate Headquarters Within Lawrence, MA 2
(Date:11/26/2014)... 25, 2014 (HealthDay News) -- Exposure to peanut protein ... allergy in infants with the skin condition eczema, a ... children in the United States are allergic to peanuts. ... food allergies, particularly peanut allergy, the researchers noted. ... to 15 months. The researchers examined the amount of ...
(Date:11/24/2014)... From embedded sensors and biometrics to elite ... will take center stage at the FitnessTech Summit , ... 2015 International CES® , January 6, 2015 in Las ... 2004). The bond between fitness and technology is stronger than ... and more about the human body. , “Fitness technology has ...
(Date:11/24/2014)... Abington, PA (PRWEB) November 24, 2014 ... Nataliya Ternopolska, MD has joined The Neurology ... Abington Health’s Multiple Sclerosis Center. , A graduate ... residency in Neurology at Albert Einstein Medical Center in ... the Judith Jaffe Multiple Sclerosis Center at Weill Cornell ...
(Date:11/24/2014)... 24, 2014 The Holiday Inn Westbury ... Family and Children's Association to donate various items ... mouthwash and other such items.The Association's program is aimed ... bound, living in nursing homes, assisted living facilities and ... the well being of seniors throughout the Long Island ...
(Date:11/24/2014)... (PRWEB) November 24, 2014 ReAdmission ... and disease management services to health plans, hospitals, ... Essette’s Medical Management software suite. ReAdmission Solutions ... in a program to reduce patients' avoidable readmissions ... Health Management, Care Management, Utilization Management, and Appeals ...
Breaking Medicine News(10 mins):Health News:Infants With Eczema May Be More Prone to Peanut Allergy: Study 2Health News:Next Wave Fitness Products Debut at FitnessTech Summit Living in Digital Times at the 2015 International CES 2Health News:Next Wave Fitness Products Debut at FitnessTech Summit Living in Digital Times at the 2015 International CES 3Health News:Next Wave Fitness Products Debut at FitnessTech Summit Living in Digital Times at the 2015 International CES 4Health News:Nataliya Ternopolska Named Associate Medical Director of Abington Health’s Multiple Sclerosis Center 2Health News:The Holiday Inn Westbury - Long Island gives back to the local Long Island community, and also goes beyond borders to assist those in need during the 2014 Holiday Season 2Health News:The Holiday Inn Westbury - Long Island gives back to the local Long Island community, and also goes beyond borders to assist those in need during the 2014 Holiday Season 3Health News:ReAdmission Solutions, LLC Selects Essette 2
... AIGISRx DEB is designed to reduce the severity of capsular ... ... capsule formation, MONMOUTH ... the commercialization of implantable medical-pharmaceutical,devices, announced today acceptance for presentation ...
... -- China Medical,Technologies, Inc. (the "Company") (Nasdaq: CMED ), a leading China-based,medical ... intensity focused ultrasound tumor,therapy systems, today announced the following investor events: Event ... ... Location UBS China Life ...
... critically needed supplies to ... clinics, fire and rescue in affected areas, SANTA ... emergency medical supplies to safety-net,clinics and has extended offers ... fires have forced 500,000 people to,evacuate their homes. ...
... Inc announced today that its,La Jolla campus will close ... to cope with San Diego County,s ongoing fire,emergency. Determination ... from the many agencies involved in dealing with the,disaster. ... by the fires so it,s,important that they take the ...
... Research and,Manufacturers of America (PhRMA) President and CEO ... wildfires: "Californians who have been affected by ... underinsured -- should know that help getting the,medicines ... for,Prescription Assistance. The PPA, sponsored by America,s pharmaceutical,research ...
... Department of,Veterans Affairs (VA) continues to offer medical care ... across parts of Southern,California., "We are grateful no ... Secretary of Veterans Affairs Gordon H. Mansfield.,"Our first priority ... The San Diego VA Medical Center and clinics remain ...
Cached Medicine News:Health News:TyRx Pharma, Inc. Announces Presentation of Results to Benefit Women with Breast Implants (In-Vivo Efficacy Study Regarding AIGISRx DEB) at the Plastic Surgery 2007 Meeting on October, 28 2007 in Baltimore, MD 2Health News:TyRx Pharma, Inc. Announces Presentation of Results to Benefit Women with Breast Implants (In-Vivo Efficacy Study Regarding AIGISRx DEB) at the Plastic Surgery 2007 Meeting on October, 28 2007 in Baltimore, MD 3Health News:China Medical Technologies to Participate in Investor Events in November 2Health News:Direct Relief International Aims California Fire Response at Health Concerns 2Health News:Help for California Fire Evacuees Possible Through Partnership for Prescription Assistance 2
Ferris Smith Rongeurs, 12 overall length 300 mm....
It is designed for rigid skeletal fixation. These pins are constructed of stainless steel and can be removed for sterilization and reuse....
It is designed for rigid skeletal fixation. These pins are constructed of stainless steel and can be removed for sterilization and reuse....
... It is designed for ... the surgeon greater freedom in ... 3-point rigid skeletal fixation is ... lateral, or sitting positions. Craniotomies ...
Medicine Products: